A Case Series on Decompensated Chronic Liver Disease with Atrial Fibrillation in Elderly

Authors

  •   G. Divya Department of Geriatric Medicine, National Centre of Ageing, Madras Medical College, Chennai - 600032, Tamil Nadu
  •   K. Uma Kalyani Department of Geriatric Medicine, National Centre of Ageing, Madras Medical College, Chennai - 600032, Tamil Nadu
  •   S. Deepa Department of Geriatric Medicine, National Centre of Ageing, Madras Medical College, Chennai - 600032, Tamil Nadu

DOI:

https://doi.org/10.65129/medical.v1i2.71

Keywords:

Anticoagulation, Atrial Fibrillation, Liver Cirrhosis, Thrombosis

Abstract

Liver cirrhosis patients are more prone to bleeding because the liver is involved in major production of coagulation and anticoagulation proteins. Also, there will be thrombocytopenia secondary to splenomegaly which increases bleeding risk. To treat patients with liver cirrhosis and atrial fibrillation with anticoagulants is complicated in so many ways. In this case series, we discussed three case scenarios of decompensated liver disease associated with atrial Fibrillation where decision making in initiating anticoagulants needed so many considerations.

Downloads

Download data is not yet available.

Downloads

Published

2025-06-30

How to Cite

Divya, G., Kalyani, K. U., & Deepa, S. (2025). A Case Series on Decompensated Chronic Liver Disease with Atrial Fibrillation in Elderly. Journal of Medical and Medical Specialities, 1(2), 105–108. https://doi.org/10.65129/medical.v1i2.71

Issue

Volume 1, Issue 2, June 2025

Section

Research Article

License

Copyright (c) 2026 Journal of Medical and Medical Specialities

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Crossref
Scopus
Google Scholar
Europe PMC

References

1. Cardiac Arrythmias. Hazzard’s Geriatric Medicine and Gerontology. New York: McGraw Hill; 2608-2618.

2. Atrial Fibrillation: Clinical features, mechanisms and management, Braunwald’s Textbook of Cardiovascular Medicine. Elsevier; 1747-60.

3. Turbo L, de Raucourt E, Valla DC, Villa E. Anticoagulation in the cirrhotic patient. JHEP Rep. 2019 16;1(3):227-239. https://doi.org/10.1016/j.jhepr.2019.02.006 PMid:32039373 PMCid:PMC7001584

4. Ballestri S, Capitelli M, Fontana CM, Arioli D, Romagnoli E, Graziosi C, et al. Direct oral anticoagulants in patients with liver disease in the era of non-alcoholic fatty liver disease global epidemic: A narrative review. Adis Journals. 2020. https://doi.org/10.6084/m9.figshare.11993394. https://doi.org/10.1007/s12325-020-01307-z PMid:32285340 PMCid:PMC7467481.

5. Serper M, Weinberg EM, Cohen JB, Reese PP, Taddei TH, Kaplan DE. Mortality and Hepatic Decompensation in patients with cirrhosis and atrial fibrillation treated with anticoagulation. Hepatology. 2021; 73(1):219-32. Epub 2020;9. https://doi.org/10.1002/hep.31264 PMid:32267547 PMCid:PMC7541418.

6. Liver cirrhosis in patients with Atrial Fibrillation: Would oral anticoagulation have a net clinical benefit for stroke prevention? J Am Heart Assoc. 2017; 6(6). https://doi.org/10.1161/JAHA.116.005307 PMid:28645935 PMCid:PMC5669162.

7. Simon TG, Singer DE, Zhang Y, Mastrorilli JM, Cervone A, DiCesare E, Lin KJ. Comparative effectiveness and safety of apixaban, rivaroxaban, and warfarin in patients with cirrhosis and atrial fibrillation : a nationwide cohort study. Ann Intern Med. 2024; 177(8):1028-1038. Epub 2024; 9.. https://doi.org/10.7326/M23-3067 PMid:38976880 PMCid:PMC11671173.